Dymon Asia Capital (Singapore) Pte. Ltd. Legend Biotech Corp Transaction History
Dymon Asia Capital (Singapore) Pte. Ltd.
- $378 Million
- Q3 2024
A detailed history of Dymon Asia Capital (Singapore) Pte. Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, Dymon Asia Capital (Singapore) Pte. Ltd. holds 12,000 shares of LEGN stock, worth $472,200. This represents 0.15% of its overall portfolio holdings.
Number of Shares
12,000Holding current value
$472,200% of portfolio
0.15%Shares
1 transactions
Others Institutions Holding LEGN
# of Institutions
216Shares Held
77.9MCall Options Held
412KPut Options Held
387K-
Price T Rowe Associates Inc Baltimore, MD11.5MShares$452 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.51MShares$295 Million5.01% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.64MShares$261 Million7.6% of portfolio
-
Black Rock Inc. New York, NY5.72MShares$225 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.04MShares$198 Million1.16% of portfolio
About Legend Biotech Corp
- Ticker LEGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 167,403,008
- Market Cap $6.59B
- Description
- Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...